Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity® catheter system and the EnligHTN™ multi-electrode renal denervation catheter by Templin, Christian et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CLINICAL RESEARCH
Vascular lesions induced by renal nerve ablation
as assessed by optical coherence tomography:
pre- and post-procedural comparison with the
Simplicityw catheter system and the EnligHTNTM
multi-electrode renal denervation catheter
Christian Templin1†, Milosz Jaguszewski1†, Jelena R. Ghadri1, Isabella Sudano1,
Roman Gaehwiler1, Jens P. Hellermann2, Renate Schoenenberger-Berzins3,
Ulf Landmesser1, Paul Erne3, Georg Noll1, and Thomas F. Lu¨scher1*
1Department of Cardiology, Cardiovascular Center, University Hospital Zurich, Raemistrasse 100, Zurich CH-8091, Switzerland; 2Division of Cardiology, Altsta¨tten Hospital, Altsta¨tten,
Switzerland; and 3Department of Cardiology, Luzerner Kantonsspital, Luzerner, Switzerland
Received 3 February 2013; revised 27 March 2013; accepted 7 April 2013; online publish-ahead-of-print 25 April 2013
This paper was guest edited by Stefano Taddei, Department of Internal Medicine, Universita` degli Studi di Pisa, Pisa, Italy.
Aims Catheter-based renal nerve ablation (RNA) using radiofrequency energy is a novel treatment for drug-resistant essential
hypertension. However, the local endothelial and vascular injury induced by RNA has not been characterized, although
this importantly determines the long-term safety of the procedure. Optical coherence tomography (OCT) enables in vivo
visualization of morphologic features with a high resolution of 10–15 mm. The objective of this study was to assess the
morphological features of the endothelial and vascular injury induced by RNA using OCT.
Methods
and results
In a prospective observational study, 32 renal arteries of patients with treatment-resistant hypertension underwent OCT
before and after RNA. All pre- and post-procedural OCT pullbacks were evaluated regarding vascular changes such as
vasospasm, oedema (notches), dissection, and thrombus formation. Thirty-two renal arteries were evaluated, in which
automatic pullbacks were obtained before and after RNA. Vasospasm was observed more often after RNA then before
the procedure (0 vs. 42%, P, 0.001). A significant decrease in mean renal artery diameter after RNA was documented
both with the EnligHTNTM (4.69+0.73 vs. 4.21+ 0.87 mm; P, 0.001) and with the Simplicityw catheter (5.04+0.66
vs. 4.57+0.88 mm; P, 0.001). Endothelial-intimal oedema was noted in 96% of cases after RNA. The presence of
thrombus formations was significantly higher after the RNA then before ablation (67 vs. 18%, P, 0.001). There was
one evidence of arterial dissection after RNA with the Simplicityw catheter, while endothelial and intimal disruptions
were noted in two patients with the EnligHTNTM catheter.
Conclusion Hereweshowthatdiffuse renal artery constriction and local tissuedamageat theablationsitewith oedemaand thrombus
formation occur after RNA and that OCT visualizes vascular lesions not apparent on angiography. This suggests that dual
antiplatelet therapy may be required during RNA.
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Introduction
Today approximately one billion people are affected by arterial
hypertension.1– 5 Data of the World Health Organization suggest
that one in three adults suffer from elevated blood pressure resulting
in a worldwide socioeconomic health problem. Indeed, the link
betweenhigh bloodpressureand increasedcardiovascular morbidity
and mortality is well established.6– 8 Despite the availability and use of
different classes of antihypertensive drugs, 5–30% of patients still
show elevated blood pressure.9 –12
Blood pressure is regulated by the sympathetic nervous
system, hormonal and endothelial factors as well as renal water
and sodiumhandling.Thekidney is innervatedbyefferent andafferent
sympathetic nerves regulating renal vascular resistance and renin
release.13 Recently, a novel catheter-based radiofrequency ablation
technique has been developed allowing for renal nerve ablation
(RNA) with a very low complication rate and without major side
effects.14 Registry data and small randomized trials have shown
that RNA effectively lowers blood pressure in patients with
treatment-resistant hypertension. Currently, two different catheter-
based systems are primarily used.15– 17 The Simplicityw catheter by
Medtronic-Adrian is a sequential denervation system allowing for de-
livery of low-power radiofrequency energy of 5–8 W at several sites
within the renal artery. The EnligHTNTM multi-electrode RNA cath-
eter from St Jude Medical consists of a multi-ablation basket with an
integrated four-point contact surface to deliver radiofrequency
energy. However, data regarding the local vascular injury induced
by the radiofrequency energy are lacking. This is of importance for
the long-term safety of the procedure, particularly since the develop-
ment of a renal artery stenosis after RNA has been reported.18
Optical coherence tomography (OCT) has been established as an
intracoronary imaging tool visualizing stent apposition and healing,
plaque characterization, thrombus formation, and dissection with a
high spatial resolution of 10–15 mm,19 which is 10-fold higher
than intravascular ultrasound (IVUS).20 Therefore, the aim of the
present study was to evaluate the morphological features before
and after renal ablation by OCT prospectively.
Methods
Patient population
This is a prospective observational double-centre study conducted at the
University Hospital of Zurich and Cantonal Hospital of Lucerne, Switzer-
land. Individuals were eligible for the study if they were.18 yearsold and
had primary and idiopathic cause of resistant arterial hypertension
defined as persistent systolic blood pressure .160 mmHg, with at
least established three antihypertensive medication (including diuretics)
or patients with allergies to antihypertensive drugs. All patients were on
daily aspirin 100 mg or received 250–500 mg aspirin intravenously
before starting the RNA procedure. One patient was on single clopido-
grel treatmentbecause of in-stent thrombosis in the past aftermyocardial
infarction. No patient was on dual antiplatelet therapy at the time of the
procedure.
Patients were excluded from the study, if glomerular filtration rate was
,45 mL/min.
Sixteen consecutive patients were included and 32 renal arteries were
accurately evaluated. All patients underwent RNA with the Simplicityw
catheter by Medtronic-Adrian or the EnligHTNTM multi-electrode by
St Jude Medical according to the operator’s discretion. All patients pro-
vided written informed consent before the procedure.
Catheter-based renal denervation procedure
The RNA procedure with the Simplicityw system (Medtronic, Minneap-
olis, MN, USA) consists of a catheter-based approach to disrupt renal
sympathetic nerves using radiofrequency energy (1 Watt) applied to
the renal artery via an electrode at the catheter tip. The catheter was
placed in the distal lumen of the main renal artery using a 6F guide via a
femoral artery access site. Then the catheter was retracted sequentially
by 5 mm each and rotated circumferentially before energy was delivered.
A total of six to eight ablations of 2 min duration were applied in each
renal artery including the complete circumference of the vessel.
RNAwith the EnligHTNTM multi-electrode renal denervation ablation
catheter (St JudeMedical Inc.,Westford,USA) involves abasket withmul-
tiple ablation surface points. The catheter was placed in the distal lumen
of the main renal artery using a 6F guide and four ablations were set se-
quentially in 90-s intervals. Afterwards a minimal catheter repositioning
was performed and the procedure was repeated more proximally.
Optical coherence tomography
All patients underwent OCT utilizing the C7-XR imaging system (Light-
Lab Imaging, Inc., Westford, USA) before and after renal denervation.
Optical coherence tomography images were performed by using a
non-occlusive acquisition technique and a single-mode optical fibre cath-
eter (frequency domain-OCT-catheter, DragonFlyTM, St Jude Medical).
In each renal artery, routinely two pullbacks were obtained pre- and
post-RNA. The OCT catheter was advanced over a conventional
0.014′ angioplasty guide wire using a monorail lumen at the tip. Renal ar-
teries were flashed of blood with Ultravist 300 (Bayer House, Berkshire,
UK) at a flow rate of 8.0 mL/s. The automated pullback and contrast in-
jection was obtained in all patients to optimize the image quality. The
acquisition sequence speed was 20 mm/s.
Optical coherence tomography evaluation
Optical coherence tomography pullbacks were analysed in a teaching
core laboratory of the Andreas Gruentzig-Catheterization Laboratory
at the University Hospital of Zurich, Switzerland, by two independent
investigators blinded to the clinical and procedural characteristics of
the patients, using a proprietary software (LightLab Imaging). Image
quality was assessed for all OCT images using a four-point scale (excel-
lent, good, moderate, non-diagnostic, and artefact). In the presence of
disagreement between the two observers, a consensus agreement was
made. All pre- and post-procedural pullbacks were evaluated for local
acute morphological vascular changes such as vasospasm, dissections,
wall oedemas (vessel notches), and thrombus formations. Lumen
and cross-sectional areas were drawn at 3 mm intervals and calculated
as appropriate. Automatic detection of mean diameter was manually
corrected frame by frame.
Lesion characterization by optical coherence
tomography
Oedema was defined as any significant endothelial– intimal notch
detected on the luminal wall surface. Vasospasm was defined by immedi-
ate loss of lumen area or lumen diameter in any part of renal artery. Endo-
thelial or intimal disruptions of the superficial intimal lining were defined
as endothelial detachments or vessel dissections. Intraluminal thrombus
was defined as a protruding mass attached to the luminal surface with a
diameter of ≥0.5 mm in at least three following cross-sections.
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Statistical analysis
Baseline characteristics are summarized using frequency tables with
count and proportion for each category, or mean and standard deviation
(SD) as appropriate. All data were checked by means of Shapiro–Wilks
W test for normal distribution. We then performed paired t-test for the
pre- and post-comparisons for continuous variables. McNemars test was
used for nominal variables.
SPSS software (Chicago, IL, USA; Version 20.0) was used for all statis-
tical analysis. A two-tailed P-value of ≤0.05 was considered as statistical
significant. Data are shown as percentages.
Results
Baseline characteristics
Sixteen patients were included based on the image quality in the final
analysis, nine males and seven females. The average age was 58.5+
9.9 years. All patients had drug-resistant hypertension (n ¼ 14) or
intolerance and/or allergy towards antihypertensive agents (n ¼ 2).
Of all patients included into the study, 56% had dyslipidaemia (n ¼ 9),
19% diabetes mellitus (n ¼ 3), 56% obesity (n ¼ 9), 38% were
current smoker at the time of inclusion (n ¼ 6), and 25% had known
coronary artery disease or a stroke (n ¼ 4). The average number of
antihypertensive drugs was 3.8+1.1. Drugs on admission, laboratory
values, and baseline characteristics are given in Table 1.
Optical coherence tomography evaluation
In total, 32 renal arteries were evaluated, in which two automatic
pullbacks had been obtained before and after RNA. Forty-four pull-
backs were performed before and after RNA with the Simplicityw
catheter and 20 with the EnligHTNTM catheter. Only good-
to-excellent quality pullbacks were included into the final analysis.
The study flow chart is presented in Figure 1. Pullbacks with
poor-to-moderate quality (n ¼ 16, with Simplicityw catheter;
n ¼ 2, with EnligHTNTM catheter) were excluded from the analysis.
Five hundred and forty-eight cross-sections with an excellent quality
were drawn to calculate lumen diameters.
Vascular spasm
We observed vasospasm in 10 renal arteries (42%) after RNA and no
vasospasm before the procedure (P, 0.001) (Table 2). Vessel spasm
was encountered along the entire length of the treated artery result-
ing in a significant reduction of the mean renal artery diameter
after the procedure. The mean renal artery diameter before and
after the procedure was 4.84+0.72 vs. 4.37+0.89 mm (P,
0.001). The difference between the mean diameter before and after
RNA was significant in both groups with the EnligHTNTM catheter
(4.69+0.73vs. 4.21+0.87 mm,P, 0.001)andtheSimplicitywcath-
eter (5.04+0.66 vs. 4.57+0.88 mm, P, 0.001) (Figures 2 and 3).
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Table 1 Baseline characteristics
All patients (n 5 16) Simplicityw (n5 11) EnligHTNTM (n5 5) P value
Age (years), mean (+SD) 58.5 (+9.9) 58.3 (+8.7) 59.0 (+13.7) 0.90
Male gender, n (%) 9 (56) 6 (55) 3 (60) 0.84
Cardiovascular risk factors, n (%)
Arterial hypertension 16 (100) 11 (100) 5 (100) 1.00
Dyslipidaemia 9 (56) 6 (55) 3 (60) 0.84
Current smoker 6 (38) 5 (45) 1 (20) 0.33
Diabetes mellitus 3 (19) 2 (18) 1 (20) 0.93
Obesity 9 (56) 5 (45) 4 (80) 0.20
Cardiovascular history, n (%)
Known CAD or stroke 4 (25) 4 (36) 0 0.12
Laboratory values, mean (+SD)
Creatinine before RNA, (mmol/L) 78.5 (+16.5) 77.2 (+20.3) 81.4 (+5.7) 0.65
Creatinine after RNA, (mmol/L) 84.5 (+23.8) 87.1 (+28.4) 79.4 (+11.9) 0.57
Medication, n (%)
ACE inhibitor 5 (31) 5 (45) 0 0.07
ARB 12 (75) 8 (73) 4 (80) 0.76
Beta-blocker 12 (75) 9 (82) 3 (60) 0.35
Calcium-channel blocker 10 (63) 6 (55) 4 (80) 0.33
Diuretics 13 (81) 9 (82) 4 (80) 0.93
Statins 8 (50) 6 (55) 2 (40) 0.59
Sum of medications per patient, mean (+SD) 3.8 (+1.1) 3.9 (+0.9) 3.4 (+1.7) 0.44
No. of patients with drug intolerance/allergy, n (%) 2 (13) 1 (9) 1 (20) 0.54
ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CAD, coronary artery disease; RNA, renal nerve ablation.
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Oedema
The OCT cross-sections showed angiographically inapparent prom-
inent vessel notches at the sites where radiofrequency-derived
energy had been delivered (Figure 4). We documented the presence
of endothelial– intimal oedema in all patients after renal denervation
with the Simplicityw catheter (n ¼ 15) and in 89% after using the
EnligHTNTM catheter (n ¼ 8). However, not all ablations points
(4–11 per renal artery) resulted in a similar degree of notch forma-
tion as documented by OCT. We notified 72 notches in all 24 pull-
backs performed after the RNA procedure. The mean amount of
vessel notches before and after RNA was 0.58+0.83 and 3.0+
2.0, respectively (P, 0.001).
Thrombus formation
We found evidence for intraluminal thrombus formation more often
after RNA than before the procedure (67 vs. 18%, P, 0.001)
(Table 2, Figure 5), 64 thrombi were documented during all pullbacks
afterRNA andonly 8 before the procedure.Also the mean amount of
thrombus formations measured per renal artery was significantly
higher after the procedure (2.67+ 2.76 vs. 0.33+0.87, P, 0.001).
Dissection
We have documented five arterial dissections/disruptions after RNA
in three renal arteries (Table 2, Figure 6).
Comparison of two catheter-based systems used
in our study: EnligHTNTM vs. Simplicityw
There was no significant difference in the amount of oedema
between the Simplicityw and the EnligHTNTM catheters measured
per renal artery (3.1+ 1.9 vs. 2.3+2.0, P ¼ 0.35). We did not
notified also any differences after the Simplicityw and the
EnligHTNTM catheters regarding the vessel spasm (40 vs. 44%, P ¼
0.83). We have documented one evidence of arterial dissection
after renal ablation with the Simplicityw catheter, while endothelial
and intimal disruptions were observed in two patients after the
EnligHTNTM catheter use (P ¼ 0.26; Figure 6).
Figure 1 Study flow chart.
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Table 2 OCT findings before and after RNA
Before RNA,
pullbacks
(n 5 22)
After RNA,
pullbacks
(n5 24)
P value
Oedema, n pullbacks (%) 10 (45) 23 (96) ,0.001
Oedema in total 14 72
Oedema per RA 0.58+0.83 3.0+2.0 ,0.001
Thrombus, n pullbacks (%) 4 (18) 16 (67) ,0.001
Thrombi in total 8 64
Thrombi per RA 0.33+0.87 2.67+2.76 ,0.001
Vasospasm, npullbacks (%) 0 10 (42) ,0.001
Vasospasm in total 0 18
Vasospasm per RA 0 0.75+1.07 0.0013
Dissection/tissue
disruption, n
pullbacks (%)
0 3 (13) 0.086
Dissection/tissue
disruption in total
0 5
Dissection per RA 0 0.21+0.59 0.09
RA, renal artery; RNA, renal nerve ablation.
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However, we observed a trend towards the intraluminal thrombus
formation, i.e. in 89% of the cases using the EnligHTNTM catheter and
in 53% with the Simplicityw catheter-based basket ablation system
(P ¼ 0.07). Moreover, a significantly greater thrombus load per renal
artery was observed after RNA with the EnligHTNTM system com-
pared with theSimplicityw system (4.6+3.1 vs. 1.5+1.8,P ¼ 0.006).
Discussion
This is the first study to evaluate prospectively the morphologic fea-
turesof RNA-induced renal vascular injuryby OCT in patients before
and after renal denervation using two different catheter systems,
i.e. the Simplicityw catheter and the EnligHTNTM multi-electrode
basket. While the feasibility and effectiveness in reducing blood pres-
sure have been documented in registries and randomized trials using
the Simplicityw catheter16,17 and to a lesser degree with the
EnligHTNTM multi-electrode basket, little is known about the vascu-
lar injury induced by the RNA procedure at the site of ablation. We
here, for the first time, demonstrate with OCT that local tissue
damage not apparent with angiography occurs, i.e. local and diffuse
vasospasm, oedema formation, and endothelial injury with thrombus
generation.
An initial observation revealed that catheter-based RNA could be
complicated by vascular lesions, i.e. vessel notches, post-procedural
vasospasm, dissections, and thrombus formations. Moreover, with
the EnligHTNTM multi-electrode system, more thrombus formation
per renal artery occurred than with the Simplicityw catheter.
In this regard, recent animal studies are of interest demonstrating
local loss of the endothelial monolayer resulting in thrombus forma-
tion even at 6 month follow-up.21,22 These observations in patients
and animal models suggest that an antithrombotic therapy should
be used before and after RNA, possibly for prolonged periods of
time. This notion is further supported by the fact that renal artery
stenosis may indeed occur after RNA, possibly evolving from such in-
juries.18
In contrast to Steigerwald, we have observed one dissection after
RNA in our series with the Simplicityw catheter.22 In this regard, one
patient of the Simplicityw HTN-1 study developed also renal artery
dissection.23 Of note, the true incidence of renal artery dissection
could be markedly underestimated in the Simplicityw HTN-1
study, since no intravascular imaging was performed in these
patients.
Local notches, which are signs of vessel wall oedema, occurred
after RNA with both catheter systems without statistically significant
difference between the two. Based on histological analyses of a
Figure3 Vasospasm of renal arteries after renal nerve ablation. Right renal artery (A–E) and left renal artery (F–J). Baseline angiography (A and F)
and OCT imaging (B andG) before renal artery ablation with the EnligHTNTM catheter. Vasospasm observed after radiofrequency therapy with both
angiography (C and H ) and OCT (D and I ). Three-dimensional OCT reconstruction of right and left renal artery after renal denervation (E and J ).
Figure 2 Changes of vessel diameter after renal nerve ablation.
Significant differences of vessel diameters before and after renal
nerve ablation were observed with both the EnligHTNTM
(St. Jude Medical) and the Simplicityw (Medtronic) catheters.
Vessel spasm was documented along the whole length of the
treated artery.
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preclinical study, notches correspond to cellular swelling and con-
nective tissue coagulation within the medial and adventitial layer.22
This formation of local oedema with water retention within the
ablated tissue and an inflammatory response is also known from elec-
trophysiological studies in which radiofrequency ablation is used. It is
assumed that such oedemas are only present in the acute phase im-
mediately after RNA and therefore a transient phenomenon of in-
flammation.21 Possibly, local oedema may reflect effective renal
denervation. Obviously, whether the larger tissue damage really
leads to a more effective decrease in blood pressure needs to be elu-
cidated. Furthermore, it is unclear whether the presence of a con-
comitant atherosclerotic disease in renal arteries has an impact on
the success of RNA on arterial blood pressure.
A three-dimensional OCT image reconstruction documented a
circumscribed vascular spasm for both catheter systems leading to
a ‘pearl-of-string’ feature with a significant reduction in the mean
renal artery diameter as well after RNA. Obviously renal vasospasm
can also result from catheter manipulation by the operator; however,
the ‘pearl-of-string’ pattern (encountered along the entire length of
the treated renal artery) strongly suggests that such a generalized
vasospasm of treated renal arteries most likely results from the
mechanical stress induced by the ablation catheter tip or basket, re-
spectively, and/or the applied radiofrequency energy itself rather
than from catheter manipulation. The mechanism of such a diffuse
vasoconstriction not only at the site of ablation remains unknown,
but may involve a reduced nitric oxide release after endothelial
damage. However, in the experience of most operators, nitrates
and calciumantagonists are not veryeffective in this context. Possibly,
endothelin release, which leads to prolonged vasospasm, may be
involved.24
Limitations
It is a limitation of this study that a rather small number of patients has
yet been studied and thus these results have to be confirmed in a
larger patient population. The comparison of both catheter-based
systems is observational and selection bias could have occurred.
However, the selection of the system was done by an independent
study coordinator who was not involved in the RNA procedure,
which would help to alleviate concerns of obvious selection bias.
Furthermore, the maximal field of view in OCT is limited to
11 mm; therefore, patients with a large renal artery diameter are dif-
ficult to study. Moreover, imaging depth is limited to 0.5–2.0 mm
Figure 4 Vessel wall oedemas after renal nerve ablation. Renal artery before (A) and after (B) Simplicityw catheter-based renal denervation.
Direct after ablation vessel notches are inapparent in angiography (B) and discernible at the lesion site by OCT imaging (C, frame and D).
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with OCT. Therefore, renal arteries with thick walls cannot be prop-
erly evaluated in their entirety. The number of pullbacks excluded
due to poor quality is much higher with the Simplicity system when
compared with the EnligHTN system. This reflects the real-world
practice for which reason we have not excluded the failed cases
from our enrolment. However, the imbalance in excluded data
could impair the validity of the analysis. Furthermore, no renal
artery flow measurements with renal duplex-sonography before
and after RNA was performed.
Conclusions
This study, for the first time, demonstrates that renal artery OCT is
feasible in most patients before and after RNA and useful to depict
acute vascular injury after the procedure. OCT after RNA allows
for a better understanding of the local vascular injury induced by dif-
ferent ablation systems. Indeed, this first experience suggests that the
EnligHTNTM multi-electrode basket induces a different tissue
response with a higher amount of thrombus formation measured
per renal artery than the Simplicityw catheter. Larger studies with
short- and long-term follow-up by OCT now need to further docu-
ment the type and extent of the healing response after RNA and the
relation between local injury and the blood pressure response after
the procedure. Based on our findings, we recommend to perform
OCT routinely in patients after RNA and to effectively inhibit platelet
activation with either acetylsalicylic acid or an ADP-receptor
antagonist.
Figure5 Thrombus formationafter renal nerveablation. Significant intraluminal thrombus formation after renal nervedenervation are inapparent
in angiography (A and D), however displayed in different OCT cross-sections (B, C, E, F and I ) and in three-dimensional reconstructed renal artery
(G and H ).
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